<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00238758</url>
  </required_header>
  <id_info>
    <org_study_id>05157</org_study_id>
    <nct_id>NCT00238758</nct_id>
  </id_info>
  <brief_title>A Study of Omega-3 as a Treatment for Major Depression</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo Controlled Trial of Omega-3 Polyunsaturated Fatty Acids as a Monotherapy for Major Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of New South Wales</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Your Health Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sphere Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ocean Nutrition</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of New South Wales</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether omega-3 polyunsaturated fatty acids are&#xD;
      effective as a monotherapy for depression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a 6 week, parallel-group, double-blind randomized controlled trial of the&#xD;
      efficacy of Omega-3 as a monotherapy for depression. People aged 21-65 who have major&#xD;
      depression but are not currently on an antidepressant or planning to take an antidepressant&#xD;
      in the next 14 weeks will be recruited. Participants will be randomly allocated to receive&#xD;
      Omega-3 (fish oil) or placebo (paraffin oil) for 6 weeks. Participants will be followed up&#xD;
      weekly and will be asked to rate their mood daily for the 6 week study period. Blood samples&#xD;
      will be taken pre and post treatment to measure change in omega-3 levels. At the end of 6&#xD;
      weeks all participants will receive a further 8 weeks supply of omega-3.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2005</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from pretreatment score on Depression Rating Scale at 6 weeks.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weekly measure of depressive symptoms</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly measure of anxiety symptoms</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly measure of functional status</measure>
  </secondary_outcome>
  <enrollment>128</enrollment>
  <condition>Major Depression</condition>
  <condition>Dysthymia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 Polyunsaturated Fatty Acids</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must meet DSM IV criteria for non-psychotic major depression lasting at least 6 weeks&#xD;
             or dysthymia.&#xD;
&#xD;
          -  Must be under the care of a mental health practitioner.&#xD;
&#xD;
          -  Must be able to give informed consent.&#xD;
&#xD;
          -  Must be able to attend the Black Dog Institute.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unsuccessful treatment with more than 2 antidepressant medications (at therapeutically&#xD;
             adequate doses and duration.&#xD;
&#xD;
          -  History of psychosis or mania/hypomania or personality disorder.&#xD;
&#xD;
          -  Non-English speaking or otherwise unable to provide historical information.&#xD;
&#xD;
          -  Having taken Omega-3 dietary supplements in the last 3 months.&#xD;
&#xD;
          -  Taking antidepressant medication for depression.&#xD;
&#xD;
          -  History of allergy to n-3 PUFA supplements, finfish or shellfish.&#xD;
&#xD;
          -  Pregnancy, breast feeding or planning to become pregnant during course of study.&#xD;
&#xD;
          -  Post-natal depression.&#xD;
&#xD;
          -  Current drug or alcohol abuse or dependence or history of abuse or dependence over the&#xD;
             last 12 months.&#xD;
&#xD;
          -  Unstable thyroid function&#xD;
&#xD;
          -  Hepatic or renal impairment or other medical conditions that may interfere with the&#xD;
             absorption and metabolism of omega-3 polyunsaturated fatty acids.&#xD;
&#xD;
          -  Coagulopathy or anticoagulant treatment.&#xD;
&#xD;
          -  Patients who, in the investigator's judgment pose a current serious suicidal or other&#xD;
             safety risk, or patients who are not likely to be able to comply with the study&#xD;
             protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Marie Rees, BSc MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Senior Research Fellow and Consultant Psychiatrist, School of Psychiatry, UNSW &amp; Black Dog Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gordon B Parker, Dsc MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Professor, School of Psychiatry UNSW and Executive Director, Black Dog Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine Owen, Bsc (hons)</last_name>
    <phone>+ 61 2 9382 4521</phone>
    <email>omega3study@unsw.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of New South Wales/ Black Dog Institute</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Owen, Bsc (hons)</last_name>
      <phone>02 9382 4521</phone>
      <email>omega3study@unsw.edu.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.blackdoginstitute.org.au</url>
    <description>Black Dog Institute website</description>
  </link>
  <link>
    <url>http://psych.med.unsw.edu.au</url>
    <description>University of NSW, school of psychiatry website</description>
  </link>
  <reference>
    <citation>Rees AM, Austin MP, Parker G. Role of omega-3 fatty acids as a treatment for depression in the perinatal period. Aust N Z J Psychiatry. 2005 Apr;39(4):274-80. Review.</citation>
    <PMID>15777365</PMID>
  </reference>
  <reference>
    <citation>Parker, G., Gibson, N., Brotchie, H., Heruc, G., Rees, A-M., Hadzi-Pavlovic, D. Omega-3 Fatty Acids and Mood Disorders. American Journal of Psychiatry(In press, 2005).</citation>
  </reference>
  <verification_date>September 2006</verification_date>
  <study_first_submitted>October 11, 2005</study_first_submitted>
  <study_first_submitted_qc>October 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2005</study_first_posted>
  <last_update_submitted>September 11, 2006</last_update_submitted>
  <last_update_submitted_qc>September 11, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2006</last_update_posted>
  <keyword>Mood Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Dysthymic Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

